Quantcast

Latest Antisense therapy Stories

2014-10-30 08:34:52

CARLSBAD, Calif., Oct. 30, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 8:30 a.m. ET in Boston, MA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com....

2014-10-01 08:30:41

CARLSBAD, Calif., Oct. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4(Rx) to treat an undisclosed ocular disease. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "Our collaboration with GSK has been very productive resulting in four drugs in development," said B. Lynne Parshall, chief operating officer at Isis. "We...

2014-09-24 08:27:33

CARLSBAD, Calif., Sept. 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 8:00 a.m. ET in New York, NY. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-09-22 08:26:16

TOORAK, Australia, Sept. 22, 2014 /PRNewswire/ -- Antisense Therapeutics (the "Company" or "ANP") is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology. The article titled "CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS", is currently available online and will be included in the print edition Volume 83, November 11, 2014. The article highlights the...

2014-09-17 08:29:10

CARLSBAD, Calif., Sept. 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $4 million milestone payment from Achaogen, Inc. (NASDAQ: AKAO) associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections. The Phase 3 study is designed as a superiority study to evaluate the efficacy and safety of plazomicin compared to colistin in patients with...

2014-09-03 08:32:52

CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-08-15 08:24:22

CARLSBAD, Calif., Aug. 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO The open-label extension study of ISIS-SMN(Rx) is offered to those children with SMA who have completed dosing in Isis'...

2014-08-04 08:28:12

- $40 million in milestone payments from partners drives improved quarterly financial performance CARLSBAD, Calif., Aug. 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,000 for the same periods in 2013. Isis' pro forma operating income in the second...

2014-08-01 08:25:54

-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which time Isis will earn an $18 million milestone payment from its...

2014-07-02 08:26:15

CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline. We look forward to continuing to advance...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related